Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
| Market Cap | 4.84B+9.0% |
| Revenue (ttm) | 618.07M+44.0% |
| Net Income | -860.21M-1368.9% |
| EPS | -14.56-1103.2% |
| Shares Out | 60.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104,677.176 |
| Open | 80.31 |
| Previous Close | 80.64 |
| Day's Range | 78.63 - 80.40 |
| 52-Week Range | 63.23 - 130.00 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 149.10(+87.81%) |
| Earnings Date | Nov 3, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MIRM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MIRM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MIRM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MIRM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
MIRM Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Product sales, net | $176.24M | 79.11% |
| Stock-based compensation | $30.11M | 13.52% |
| Acquired IPR&D | $16.43M | 7.38% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New MIRM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MIRM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MIRM
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $162.01M |
| VBVanguard Morningstar Small-Cap ETF | $117.02M |
| XBIState Street SPDR S&P Biotech ETF | $102.01M |
| IWMiShares Russell 2000 ETF | $100.50M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $67.16M |
| VXFVanguard Extended Market ETF | $54.93M |
Estimated from each fund’s disclosed top holdings × AUM
MIRM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MIRM’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score